Sands BE - Search Results

1

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.

Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, Greenbloom S. Sands BE, et al. Inflamm Bowel Dis. 2010 Jul;16(7):1209-18. doi: 10.1002/ibd.21159. Inflamm Bowel Dis. 2010. PMID: 19918967 Clinical Trial.

2

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.

Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Sands BE, et al. Gastroenterology. 1999 Jul;117(1):58-64. doi: 10.1016/s0016-5085(99)70550-0. Gastroenterology. 1999. PMID: 10381910 Clinical Trial.

3

Medical therapy of steroid-resistant Crohn's disease.

Sands BE. Sands BE. Can J Gastroenterol. 2000 Sep;14 Suppl C:33C-37C. doi: 10.1155/2000/805015. Can J Gastroenterol. 2000. PMID: 11023559 Review.

4

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Sands BE, et al. Inflamm Bowel Dis. 2001 May;7(2):83-8. doi: 10.1097/00054725-200105000-00001. Inflamm Bowel Dis. 2001. PMID: 11383595 Clinical Trial.

5

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group. Sands BE, et al. Aliment Pharmacol Ther. 2002 Mar;16(3):399-406. doi: 10.1046/j.1365-2036.2002.01179.x. Aliment Pharmacol Ther. 2002. PMID: 11876692 Free article. Clinical Trial.

6

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Free article. Clinical Trial.

7

Guidelines for immunizations in patients with inflammatory bowel disease.

Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. Sands BE, et al. Inflamm Bowel Dis. 2004 Sep;10(5):677-92. doi: 10.1097/00054725-200409000-00028. Inflamm Bowel Dis. 2004. PMID: 15472534

8

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.

Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Sands BE, et al. Clin Gastroenterol Hepatol. 2004 Oct;2(10):912-20. doi: 10.1016/s1542-3565(04)00414-8. Clin Gastroenterol Hepatol. 2004. PMID: 15476155 Clinical Trial.

9

A survey of methodological variation in the Crohn's disease activity index.

Sands BE, Ooi CJ. Sands BE, et al. Inflamm Bowel Dis. 2005 Feb;11(2):133-8. doi: 10.1097/00054725-200502000-00006. Inflamm Bowel Dis. 2005. PMID: 15677906

10

Design issues and outcomes in IBD clinical trials.

Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Sands BE, et al. Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S22-8. doi: 10.1097/01.mib.0000184849.38816.39. Inflamm Bowel Dis. 2005. PMID: 16254479 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

353 results

Search Page